US › Healthcare

Tscan Therapeutics Inc (TCRX)

US · Healthcare · Biotechnology

$0.23-3.35%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$1.1M

Revenue YoY

-65.8%

Net profit

$-30.4M

EPS

$-0.23

EPS estimate

$-0.29

Net margin

-2,888.6%

EPS came in at -0.23 against a street estimate of -0.29 — a beat of 20.7%.

Key statistics

Market cap

$15.6M

Forward P/E

0.0

P/B

0.36

Book value

$1.02

EPS (TTM)

$-0.91

52-week high

$2.57

52-week low

$0.22

50-day MA

$0.54

200-day MA

$0.92

Beta

1.14

Analyst view

Analysts rate Tscan Therapeutics Inc a hold (1 buy, 4 hold, 0 sell out of 5) with an average price target of $1.00.

Shareholding

Insiders

1.76%

Institutions

67.88%

Largest institutional holders

Fund	Stake
Lynx1 Capital Management, LP	11.83%
Bvf Inc	8.21%
Baker Bros Advisors LP	4.11%
Vanguard Capital Management, LLC	3.19%
Two Sigma Investments LLC	2.88%
Renaissance Technologies Corp	1.96%
Acadian Asset Management LLC	1.93%
Deer Management Co. LLC	1.84%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tscan Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.